Curevac slumps on poor COVID-19 clinical trials
Shares in Curevac have crashed by 50% after early data revealed its COVID-19 vaccine is only 47% effective. This compared to over 90% effectiveness for Moderna and Pfizer vaccines. IGTV’s Victoria Scholar looks at the chart.
Related articles
Live prices on most popular markets
- Equities
- Indices
- Forex
- Commodities
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.